Biological Drug API Manufacturing Services Market Report 2021-2031

生物学的製剤API製造サービスの世界市場2021年-2031年

◆タイトル:Biological Drug API Manufacturing Services Market Report 2021-2031
◆商品コード:VGA21MA046
◆調査・発行会社:visiongain
◆発行日:2021年1月
◆ページ数:353
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:サービス
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD4,549 ⇒換算¥0見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥0見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、世界の生物学的製剤API製造サービスの世界市場について調査・分析し、レポート概要、エグゼクティブサマリー、産業インサイト、製造種類別(外部委託、施設内)分析、発現プラットフォーム別(哺乳類細胞培養、微生物発酵、その他)分析、用途別(ワクチン、MAB、インスリンアナログ、インターフェロン療法、ヒト成長ホルモン)分析、地域別分析、企業情報などの項目を掲載しています。
・レポート概要
・エグゼクティブサマリー
・産業インサイト
・世界の生物学的製剤API製造サービス市場規模:製造種類別(外部委託、施設内)
・世界の生物学的製剤API製造サービス市場規模:発現プラットフォーム別(哺乳類細胞培養、微生物発酵、その他)
・世界の生物学的製剤API製造サービス市場規模:用途別(ワクチン、MAB、インスリンアナログ、インターフェロン療法、ヒト成長ホルモン)
・世界の生物学的製剤API製造サービス市場規模:地域別
・企業情報

Biological Drug API Manufacturing Services Set to Witness Significant Growth Over Next 10 Years

The opportunity to become a market leader in the rapidly growing biosimilar industry has spurred many companies to invest in biosimilar development, either directly or through a partnership with a more experienced CMO. Currently, in 2020, there are over 55 approved biosimilars in the EU and the market for these products is expected to grow rapidly in the coming 10 years. Demand for lower-cost biological therapies in developed and emerging markets, as well as patent expires for blockbuster biologics, will drive investment in biosimilar development. CMOs that can offer expertise and biomanufacturing capacity will benefit from contracts with biosimilar developers, such as small molecule generic drug manufacturers, as well as emerging biosimilar manufacturers looking to launch their follow-on biologics in developed markets.

U.S. Holds the Maximum Market Share in Global Biological Drug API Manufacturing Services Market

The US is the global leader of the biological drug API manufacturing service market and this is no surprise as it also has the highest level of demand worldwide for pharmaceuticals, including outsourced API manufacturing. Per person, the US spends around one thousand dollars a year on pharmaceuticals, higher than any other country in the world. Additionally, pharmaceuticals cost more in the US, with some drugs being twice the price they are in the UK and Canada. This is because the US government does not regulate its pharma prices. Furthermore, the opaque US health system makes it hard to draw drug-by-drug comparisons with prices abroad. The majority of the leading biotech CMOs have facilities in the United States, which provide APIs domestically. In 2020, US market accounted for US$ xx million, or over 90%, of the North American biological drug API manufacturing services revenues. Emerging markets are no longer as cheap as they used to be and additionally, emerging markets do not always meet quality standards. This deficiency in standards and rise in costs because of the demands for compliance to standards has increased the demand in the US market. Local manufacturers can also provide products more conveniently, as there are less communication or timing issues.

Discover how to stay ahead

Our 350+ page report provides 350+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biological Drug API Manufacturing Services Market. See how to exploit the opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets.

By Manufacturing Type
• Outsourced
• In-house
By Expression Platform
• Mammalian Cell Cultures
• Microbial Fermentations
• Others
By Application
• Vaccines
• MABs
• Insulin Analogues
• Interferon Therapies
• Human Growth Hormones
• Other Therapeutic Areas
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 22 leading national markets:

By Region
• North America
U.S.

Canada
• Europe
Germany

France

UK

Italy

Spain

Russia

Switzerland

Netherlands

Rest of Europe
• Asia Pacific
China

Japan

India

Australia

South Korea

Singapore

Rest of Asia Pacific
• Latin America
Brazil

Mexico

Colombia

Argentina

Rest of Latin America
• Middle East & Africa
GCC

South Africa

Rest of Middle East & Africa

Leading companies and the potential for market growth

Overall world revenue for Biological Drug API Manufacturing Services Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biological Drug API Manufacturing Services Market report helps you

In summary, our 350+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Biological Drug API Manufacturing Services Market, with forecasts for Manufacturing Type, Expression Platform, and Application, each forecasted at a global and regional leveldiscover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 22 key national marketsSee forecasts for the Biological Drug API Manufacturing Services market in North America, Europe, Asia Pacific, and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, Singapore, among other prominent economies.
• Prospects for established firms and those seeking to enter the marketincluding company profiles for 10 of the major companies involved in the Biological Drug API Manufacturing Services Market. Some of the company’s profiled in this report include Bristol-Myers Squibb Co., Samsung Biologics, AbbVie, GSK Biopharmaceuticals, Lonza Group Ltd., NEKTAR THERAPEUTICS, Boehringer, Patheon N.V., Cytovance Biologics, and Fujifilm Diosynth Biotechnologies.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

【レポートの目次】

1. Report Overview
1.1 Introduction to Biological Drug API Manufacturing Services Market
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 COVID-19 Impact: Recovery Scenarios
1.6.2 Market Evaluation & Forecasting Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Industry Insights
3.1 Drivers
3.1.1 Biological Patent Expirations to Fuel Market Growth
3.1.2 Outsourcing as a Driver for Market Growth
3.1.3 Growing Investments in Orphan Drugs
3.1.4 Emerging Economies to Offer Lucrative Growth Opportunities
3.1.5 Single Use Technology will Become Essential Over the Next Decade
3.2 Restraints
3.2.1 Manufacturing APIs for Biologics to Restrain Market Growth
3.2.2 Pricing Pressure to Impede Market Growth Through 2031
3.2.3 Regulatory Scenarios to Restrain Market Growth
3.2.4 Excessive Production is Projected to Impede Market Growth
3.2.5 API Production is a Challenging Task
3.3 SWOT Analysis
3.3.1 Strengths
3.3.2 Weaknesses
3.3.3 Opportunities
3.3.4 Threats
3.4 Industry analysis – PEST Analysis
3.4.1 Political
3.4.2 Economical
3.4.3 Social
3.4.4 Technological
4 Biological Drug API Manufacturing Services Market by Manufacturing Type
4.1 Outsourced Segment Market Forecast, 2021-2031
4.1.1 Recovery Scenarios (V, U, W, L)
4.2 In-house Segment Market Forecast, 2021-2031
4.2.1 Recovery Scenarios (V, U, W, L)
5 Biological Drug API Manufacturing Services Market by Expression Platform
5.1 Mammalian Cell Cultures Segment Market Forecast, 2021-2031
5.1.1 Introduction
5.1.2 Recovery Scenarios (V, U, W, L)
5.2 Microbial Fermentations Segment Market Forecast, 2021-2031
5.2.1 Introduction
5.2.2 Recovery Scenarios (V, U, W, L)
5.3 Others Segment Market Forecast, 2021-2031
5.3.1 Introduction
5.3.2 Recovery Scenarios (V, U, W, L)
6 Biological Drug API Manufacturing Services Market by Application
6.1 Vaccines Segment Market Forecast, 2021-2031
6.1.1 Introduction
6.1.2 Recovery Scenarios (V, U, W, L)
6.2 MABs Segment Market Forecast, 2021-2031
6.2.1 Introduction
6.2.2 Recovery Scenarios (V, U, W, L)
6.3 Insulin Analogues Segment Market Forecast, 2021-2031
6.3.1 Introduction
6.3.2 Recovery Scenarios (V, U, W, L)
6.4 Interferon Therapies Segment Market Forecast, 2021-2031
6.4.1 Introduction
6.4.2 Recovery Scenarios (V, U, W, L)
6.5 Human Growth Hormones Segment Market Forecast, 2021-2031
6.5.1 Introduction
6.5.2 Recovery Scenarios (V, U, W, L)
6.6 Other Therapeutic Areas Segment Market Forecast, 2021-2031
6.6.1 Recovery Scenarios (V, U, W, L)
7 Regional and Leading National Biological Drug API Manufacturing Services Market Forecasts 2021-2031
7.1 Global Biological Drug API Manufacturing Services Market by Region Forecast 2021-2031
7.2 Recovery Scenarios (V, U, W, L)
8 North America Biological Drug API Manufacturing Services Market, 2021-2031
8.1 North America Biological Drug API Manufacturing Services Market by Country Forecast 2021-2031
8.2 U.S. Biological Drug API Manufacturing Services Market Forecast, 2021-2031
8.2.1 Largest Biological Drug API Manufacturing Market Across the Globe
8.2.2 Biologics Approved by FDA in 2019
8.2.3 Recovery Scenarios (V, U, W, L): U.S. Biological Drug API Manufacturing Services Market Forecast, 2021-2031
8.3 Canada Biological Drug API Manufacturing Services Market Forecast, 2021-2031
8.3.1 Growing Entrance of Biosimilars in Canadian Market
8.3.2 Recovery Scenarios (V, U, W, L): Canada Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9 Europe Biological Drug API Manufacturing Services Market, 2021-2031
9.1 Europe Biological Drug API Manufacturing Services Market by Country Forecast 2021-2031
9.2 Germany Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.2.1 Germany Has Well Established Biomanufacturing Industry
9.2.2 Recovery Scenarios (V, U, W, L): Germany Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.3 France Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.3.1 France is one of the Leading Pharmaceutical Manufacturing Industry in Europe
9.3.2 Recovery Scenarios (V, U, W, L): France Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.4 UK Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.4.1 Strong Biopharma Industry Across UK to Fuel Market Growth
9.4.2 Recovery Scenarios (V, U, W, L): UK Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.5 Italy Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.5.1 Recovery Scenarios (V, U, W, L): Italy Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.6 Spain Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.6.1 Recovery Scenarios (V, U, W, L): Spain Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.7 Russia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.7.1 Recovery Scenarios (V, U, W, L): Russia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.8 Switzerland Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.8.1 Recovery Scenarios (V, U, W, L): Switzerland Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.9 Netherlands Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.9.1 Recovery Scenarios (V, U, W, L): Netherlands Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.10 Rest of Europe Biological Drug API Manufacturing Services Market Forecast, 2021-2031
9.10.1 Recovery Scenarios (V, U, W, L): Rest of Europe Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10 Asia Pacific Biological Drug API Manufacturing Services Market, 2021-2031
10.1 Asia Pacific Biological Drug API Manufacturing Services Market by Country Forecast 2021-2031
10.2 Japan Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.2.1 Increased Competition from U.S. in Generics and Patented Environment, and China in Terms of API
10.2.2 Japanese Government to Cut Healthcare Costs to Boost Generics and Biosimilar Sectors
10.2.3 Recovery Scenarios (V, U, W, L): Japan Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.3 India Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.3.1 India Biological Drug API Manufacturing Services Market to Witness Fastest Growth Rate from 2021 to 2031
10.3.2 Infusion of US$ 1.2 billion in Pharmaceutical Industry by Indian Government to Boost Domestic API Capabilities Amid COVID-19
10.3.3 Growing Public Healthcare Sector to Fuel Market Growth
10.3.4 Recovery Scenarios (V, U, W, L): India Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.4 China Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.4.1 China is Most Popular Outsourcing Destination
10.4.2 Challenges Amid COVID-19
10.4.3 Recovery Scenarios (V, U, W, L): China Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.5 Australia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.5.1 Availability of Biologics & Biosimilar Medicines is Anticipated to Have a Positive Impact on Australian Healthcare System
10.5.2 Recovery Scenarios (V, U, W, L): Australia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.6 South Korea Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.6.1 Samsung Biologics Expansion Plan to Offer Lucrative Growth Opportunities for South Korean Market
10.6.2 Recovery Scenarios (V, U, W, L): South Korea Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.7 Singapore Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.7.1 Evolving Pharmaceutical Industry
10.7.2 Singapore Has Well Developed & Established Pharma Market
10.7.3 Recovery Scenarios (V, U, W, L): Singapore Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.8 Rest of Asia Pacific Biological Drug API Manufacturing Services Market Forecast, 2021-2031
10.8.1 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11 Latin America Biological Drug API Manufacturing Services Market, 2021-2031
11.1 Latin America Biological Drug API Manufacturing Services Market by Country Forecast 2021-2031
11.2 Brazil Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.2.1 Recovery Scenarios (V, U, W, L): Brazil Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.3 Argentina Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.3.1 Recovery Scenarios (V, U, W, L): Argentina Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.4 Mexico Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.4.1 Introduction
11.4.2 Recovery Scenarios (V, U, W, L): Mexico Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.5 Colombia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.5.1 Recovery Scenarios (V, U, W, L): Colombia Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.6 Rest of Latin America Biological Drug API Manufacturing Services Market Forecast, 2021-2031
11.6.1 Recovery Scenarios (V, U, W, L): Rest of Latin America Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12 Middle East and Africa Biological Drug API Manufacturing Services Market, 2021-2031
12.1 Middle East and Africa Biological Drug API Manufacturing Services Market by Country Forecast 2021-2031
12.2 GCC Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12.2.1 Recovery Scenarios (V, U, W, L): GCC Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12.3 South Africa Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12.3.1 Recovery Scenarios (V, U, W, L): South Africa Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12.4 Rest of Middle East and Africa Biological Drug API Manufacturing Services Market Forecast, 2021-2031
12.4.1 Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Biological Drug API Manufacturing Services Market Forecast, 2021-2031
13 Company Profiles
13.1 Bristol-Myers Squibb Co.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis, 2015-2019
13.1.4 Product Benchmarking
13.1.5 Recent Developments, 2018-2020
13.2 Samsung Biologics Co., Ltd.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis, 2015 to 2019
13.2.4 Product Benchmarking
13.2.5 Recent Developments, 2019 to 2020
13.3 Abbvie Inc.
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis, 2015 to 2019
13.3.4 Product Benchmarking
13.3.5 Recent Developments, 2018 to 2020
13.4 GlaxoSmithKline Plc
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis, 2015 to 2019
13.4.4 Product Benchmarking
13.4.5 Recent Developments, 2018 to 2020
13.5 Lonza Group
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis, 2015 to 2019
13.6 Teva Pharmaceutical Industries Ltd.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis, 2015 to 2019
13.7 Piramal Enterprises Ltd
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis, 2015 to 2019
13.8 Boehringer Ingelheim International GmbH
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis, 2015 to 2019
13.8.4 Product Benchmarking
13.8.5 Recent Developments, 2018 to 2020
13.9 Catalent Inc.
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis, 2015 to 2019
13.10 Nektar Therapeutics
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Analysis, 2015 to 2019
13.10.4 Product Benchmarking
13.10.5 Recent Developments, 2018 to 2020
13.11 UCB SA
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis, 2015 to 2019
13.11.4 Product Benchmarking
13.11.5 Recent Developments, 2018 to 2020
13.12 Biogen Inc.
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis, 2015 to 2019
13.12.4 Product Benchmarking
13.12.5 Recent Developments, 2018 to 2020
13.13 Biocon
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis, 2015 to 2019
13.13.4 Product Benchmarking
13.13.5 Recent Developments, 2018 to 2020
13.14 Regeneron Pharmaceuticals, Inc.
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis, 2015 to 2019
13.14.4 Product Benchmarking
13.14.5 Recent Developments, 2018 to 2020
13.15 Sandoz
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Product Benchmarking
13.15.4 Recent Developments, 2018 to 2020
13.16 Fujifilm Diosynth Biotechnologies
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Product Benchmarking
13.16.4 Recent Developments, 2018 to 2020
14 Conclusion



★調査レポート[生物学的製剤API製造サービスの世界市場2021年-2031年] ( Biological Drug API Manufacturing Services Market Report 2021-2031 / VGA21MA046) 販売に関する免責事項
[生物学的製剤API製造サービスの世界市場2021年-2031年] ( Biological Drug API Manufacturing Services Market Report 2021-2031 / VGA21MA046) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆